Literature DB >> 21781998

Next generation dengue vaccines: a review of candidates in preclinical development.

Julia Schmitz1, John Roehrig, Alan Barrett, Joachim Hombach.   

Abstract

Dengue represents a major public health problem of growing global importance. In the absence of specific dengue therapeutics, strategies for disease control have increasingly focused on the development of dengue vaccines. While a licensed dengue vaccine is not yet available, several vaccine candidates are currently being evaluated in clinical trials and are described in detail in accompanying articles. In addition, there are a large variety of candidates in preclinical development, which are based on diverse technologies, ensuring a continued influx of innovation into the development pipeline. Potentially, some of the current preclinical candidates may become next generation dengue vaccines with superior product profiles. This review provides an overview of the various technological approaches to dengue vaccine development and specifically focuses on candidates in preclinical development.
Copyright © 2011 World Health Organization. Published by Elsevier Ltd.. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21781998     DOI: 10.1016/j.vaccine.2011.07.017

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  45 in total

Review 1.  Dengue epidemiology and pathogenesis: images of the future viewed through a mirror of the past.

Authors:  Rashedul Islam; Mohammed Salahuddin; Md Salahuddin Ayubi; Tahmina Hossain; Apurba Majumder; Andrew W Taylor-Robinson; Abdullah Mahmud-Al-Rafat
Journal:  Virol Sin       Date:  2015-10-20       Impact factor: 4.327

2.  An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.

Authors:  Laura J White; Carlos A Sariol; Melissa D Mattocks; Wahala Wahala M P B; Vorraphun Yingsiwaphat; Martha L Collier; Jill Whitley; Rochelle Mikkelsen; Idia V Rodriguez; Melween I Martinez; Aravinda de Silva; Robert E Johnston
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

3.  Introduction.

Authors:  Michael Nathan
Journal:  Pathog Glob Health       Date:  2012-12       Impact factor: 2.894

Review 4.  Fight against dengue in India: progresses and challenges.

Authors:  Bhavna Gupta; B P Niranjan Reddy
Journal:  Parasitol Res       Date:  2013-02-28       Impact factor: 2.289

Review 5.  Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment.

Authors:  Tim K Mackey; Bryan A Liang; Raphael Cuomo; Ryan Hafen; Kimberly C Brouwer; Daniel E Lee
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

6.  Dengue dynamics and vaccine cost-effectiveness in Brazil.

Authors:  David P Durham; Martial L Ndeffo Mbah; Jan Medlock; Paula M Luz; Lauren A Meyers; A David Paltiel; Alison P Galvani
Journal:  Vaccine       Date:  2013-06-20       Impact factor: 3.641

7.  The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1.

Authors:  Yang Zhou; S Kyle Austin; Daved H Fremont; Boyd L Yount; Jeremy P Huynh; Aravinda M de Silva; Ralph S Baric; William B Messer
Journal:  Virology       Date:  2013-02-28       Impact factor: 3.616

Review 8.  Vaccines for viral hemorrhagic fevers--progress and shortcomings.

Authors:  Darryl Falzarano; Heinz Feldmann
Journal:  Curr Opin Virol       Date:  2013-06-15       Impact factor: 7.090

9.  Potential opportunities and perils of imperfect dengue vaccines.

Authors:  Isabel Rodriguez-Barraquer; Luis Mier-y-Teran-Romero; Ira B Schwartz; Donald S Burke; Derek A T Cummings
Journal:  Vaccine       Date:  2013-11-19       Impact factor: 3.641

10.  Country- and age-specific optimal allocation of dengue vaccines.

Authors:  Martial L Ndeffo Mbah; David P Durham; Jan Medlock; Alison P Galvani
Journal:  J Theor Biol       Date:  2013-10-23       Impact factor: 2.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.